Stock CLPT CLEARPOINT NEURO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News ClearPoint Neuro, Inc.

Equities

CLPT

US18507C1036

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
5.26 USD -0.94% Intraday chart for ClearPoint Neuro, Inc. -1.31% -22.53%
Apr. 24 ClearPoint Neuro, Inc. Announces Initiation of Limited Market Release for the SmartFrame OR? Stereotactic System CI
Apr. 16 ClearPoint Neuro Says Partner AviadoBio Treats First Person in Trial of AVB-101 for Frontotemporal Dementia MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ClearPoint Neuro Announces Initiation of Limited Market Release for the SmartFrame OR Stereotactic System
AQ
ClearPoint Neuro Announces Initiation of Limited Market Release for the SmartFrame OR™ Stereotactic System
AQ
ClearPoint Neuro, Inc. Announces Initiation of Limited Market Release for the SmartFrame OR? Stereotactic System
CI
ClearPoint Neuro to Announce First Quarter 2024 Results May 7, 2024
AQ
ClearPoint Neuro Says Partner AviadoBio Treats First Person in Trial of AVB-101 for Frontotemporal Dementia
MT
ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
GL
Purcell & Lefkowitz LLP Announces Shareholder Investigation of ClearPoint Neuro, Inc. (NASDAQ: CLPT)
PR
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza as a Treatment for AADC Deficiency
AQ
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency
AQ
Stifel Adjusts Price Target on ClearPoint Neuro to $9 From $8, Maintains Buy Rating
MT
ClearPoint Neuro, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Transcript : ClearPoint Neuro, Inc., Q4 2023 Earnings Call, Mar 12, 2024
Earnings Flash (CLPT) CLEARPOINT NEURO Posts Q4 Revenue $6.8M, vs. Street Est of $6.5M
MT
ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results
AQ
ClearPoint Neuro, Inc. Reaffirms Revenue Guidance for the Year 2024
CI
Journal of Neurosurgery Publication Demonstrates Distinct Advantages of ClearPoint Prism® Neuro Laser Therapy System
AQ
ClearPoint Neuro, Inc. Announces Preclinical Results of an in Vivo Validation Study Have Been Published in the Journal of Neurosurgery
CI
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024
AQ
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024
AQ
ClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CLPT Stock
  4. News ClearPoint Neuro, Inc.